

Toshiyoshi Fujiwara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4970376/publications.pdf>

Version: 2024-02-01

185
papers

5,661
citations

71102

41
h-index

102487

66
g-index

193
all docs

193
docs citations

193
times ranked

5829
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute acalculous cholecystitis caused by SARS-CoV-2 infection: A case report and literature review. <i>International Journal of Surgery Case Reports</i> , 2022, 90, 106731.	0.6	9
2	Effectiveness of early exercise on reducing skeletal muscle loss during preoperative neoadjuvant chemotherapy for esophageal cancer. <i>Surgery Today</i> , 2022, 52, 1143-1152.	1.5	8
3	Surgical resection of mixed neuroendocrine-non-neuroendocrine neoplasm in the biliary system: a report of two cases. <i>Surgical Case Reports</i> , 2022, 8, 38.	0.6	1
4	Tumor-targeted fluorescence labeling systems for cancer diagnosis and treatment. <i>Cancer Science</i> , 2022, 113, 1919-1929.	3.9	3
5	Modulation of p53 expression in cancer-associated fibroblasts prevents peritoneal metastasis of gastric cancer. <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 249-261.	4.4	7
6	Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1405-1417.	4.2	19
7	Extracellular vesicles shed from gastric cancer mediate protumor macrophage differentiation. <i>BMC Cancer</i> , 2021, 21, 102.	2.6	10
8	Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 879.	4.1	8
9	Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer. <i>Scientific Reports</i> , 2021, 11, 1693.	3.3	48
10	Role of Tumor-Associated Macrophages in Sarcomas. <i>Cancers</i> , 2021, 13, 1086.	3.7	26
11	Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: Clinicopathologic, transcriptomic and immunologic analyses. <i>International Journal of Cancer</i> , 2021, 149, 546-560.	5.1	18
12	Oncolytic virotherapy promotes radiosensitivity in soft tissue sarcoma by suppressing anti-apoptotic MCL1 expression. <i>PLoS ONE</i> , 2021, 16, e0250643.	2.5	4
13	Nanog is a promising chemoresistant stemness marker and therapeutic target by iron chelators for esophageal cancer. <i>International Journal of Cancer</i> , 2021, 149, 347-357.	5.1	12
14	Efficacy and safety of short-term (3 days) enoxaparin in preventing venous thromboembolism after gastric cancer surgery: A single-center, prospective cohort study. <i>International Journal of Surgery</i> , 2021, 89, 105946.	2.7	4
15	Early intervention of the perioperative multidisciplinary team approach decreases the adverse events during neoadjuvant chemotherapy for esophageal cancer patients. <i>Esophagus</i> , 2021, 18, 797-805.	1.9	6
16	Local oncolytic adenovirotherapy produces an abscopal effect via tumor-derived extracellular vesicles. <i>Molecular Therapy</i> , 2021, 29, 2920-2930.	8.2	14
17	Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 513-524.	2.3	6
18	Immuno-hyperthermia effected by antibody-conjugated nanoparticles selectively targets and eradicates individual cancer cells. <i>Cell Cycle</i> , 2021, 20, 1221-1230.	2.6	5

#	ARTICLE	IF	CITATIONS
19	Hyperthermia generated by magnetic nanoparticles for effective treatment of disseminated peritoneal cancer in an orthotopic nude-mouse model. <i>Cell Cycle</i> , 2021, 20, 1122-1133.	2.6	6
20	ASO Visual Abstract: Prediction of Early Hepatocellular Carcinoma Recurrence After Resection—An International Validation of the ERASL Risk Models. <i>Annals of Surgical Oncology</i> , 2021, 28, 505-506.	1.5	0
21	Prediction of Early Recurrence After Surgery for Liver Tumor (ERASL): An International Validation of the ERASL Risk Models. <i>Annals of Surgical Oncology</i> , 2021, 28, 8211-8220.	1.5	6
22	Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments. <i>European Journal of Cancer</i> , 2021, 153, 98-108.	2.8	25
23	Paraesophageal hernia repair can decrease BNP levels. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 6921-6929.	2.4	2
24	Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer. <i>Esophagus</i> , 2020, 17, 127-134.	1.9	15
25	A novel modified hanging maneuver in laparoscopic left hemihepatectomy. <i>International Journal of Surgery Case Reports</i> , 2020, 76, 251-253.	0.6	2
26	Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 14-23.	4.4	13
27	Efficacy of surgical management for recurrent intrahepatic cholangiocarcinoma: A multi-institutional study by the Okayama Study Group of HBP surgery. <i>PLoS ONE</i> , 2020, 15, e0238392.	2.5	10
28	FUCCI Real-Time Cell-Cycle Imaging as a Guide for Designing Improved Cancer Therapy: A Review of Innovative Strategies to Target Quiescent Chemo-Resistant Cancer Cells. <i>Cancers</i> , 2020, 12, 2655.	3.7	16
29	Intraoperative fluid therapy and postoperative complications during minimally invasive esophagectomy for esophageal cancer: a single-center retrospective study. <i>Journal of Anesthesia</i> , 2020, 34, 404-412.	1.7	10
30	Skeletal muscle loss in the postoperative acute phase after esophageal cancer surgery as a new prognostic factor. <i>World Journal of Surgical Oncology</i> , 2020, 18, 143.	1.9	18
31	Boosting Replication and Penetration of Oncolytic Adenovirus by Paclitaxel Eradicate Peritoneal Metastasis of Gastric Cancer. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 262-271.	4.4	21
32	Systematic review on immunonutrition in partial pancreatoduodenectomy. <i>Langenbeck's Archives of Surgery</i> , 2020, 405, 585-593.	1.9	10
33	Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy. <i>Cancers</i> , 2020, 12, 478.	3.7	17
34	Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody. <i>Molecular Therapy</i> , 2020, 28, 794-804.	8.2	42
35	Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 107-117.	4.4	25
36	Upregulation of microRNA-31 is associated with poor prognosis in patients with advanced colorectal cancer. <i>Oncology Letters</i> , 2020, 19, 2685-2694.	1.8	6

#	ARTICLE	IF	CITATIONS
37	Title is missing!. , 2020, 15, e0238392.		0
38	Title is missing!. , 2020, 15, e0238392.		0
39	Title is missing!. , 2020, 15, e0238392.		0
40	Title is missing!. , 2020, 15, e0238392.		0
41	The Outcome of Complex Hepato-Pancreato-Biliary Surgery for Elderly Patients: A Propensity Score Matching Analysis. Digestive Surgery, 2019, 36, 323-330.	1.2	8
42	Multidisciplinary oncolytic virotherapy for gastrointestinal cancer. Annals of Gastroenterological Surgery, 2019, 3, 396-404.	2.4	10
43	Visualization of epithelial-mesenchymal transition in an inflammatory microenvironmentâ€“colorectal cancer network. Scientific Reports, 2019, 9, 16378.	3.3	29
44	Intraperitoneal cancer-immune microenvironment promotes peritoneal dissemination of gastric cancer. Oncoimmunology, 2019, 8, e1671760.	4.6	27
45	Acquired resistance mechanisms to afatinib in <i>HER2</i> -amplified gastric cancer cells. Cancer Science, 2019, 110, 2549-2557.	3.9	26
46	Recent Changes and Improvements in Multidisciplinary Perioperative Management From a Nutritional Perspective: Dental Specialty Should Be Considered Important. Current Oral Health Reports, 2019, 6, 70-75.	1.6	1
47	Photoimmunotherapy for cancer-associated fibroblasts targeting fibroblast activation protein in human esophageal squamous cell carcinoma. Cancer Biology and Therapy, 2019, 20, 1234-1248.	3.4	48
48	Higher human lymphocyte antigen class I expression in earlyâ€“stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes. Cancer Science, 2019, 110, 1842-1852.	3.9	9
49	A Novel Combination Cancer Therapy with Iron Chelator Targeting Cancer Stem Cells via Suppressing Stemness. Cancers, 2019, 11, 177.	3.7	21
50	O76 MICROANATOMY BASED STANDARDIZATION OF LEFT UPPER MEDIASTINAL LYMPH NODE DISSECTION IN THORACOSCOPIC ESOPHAGECTOMY IN THE PRONE POSITION. Ecological Management and Restoration, 2019, 32, .	0.4	0
51	Cancer-associated fibroblasts (CAFs) promote the lymph node metastasis of esophageal squamous cell carcinoma. International Journal of Cancer, 2019, 144, 828-840.	5.1	78
52	Detection of circulating microRNAs with Ago2 complexes to monitor the tumor dynamics of colorectal cancer patients during chemotherapy. International Journal of Cancer, 2019, 144, 2169-2180.	5.1	22
53	Effect of an enhanced recovery after surgery protocol in patients undergoing pancreaticoduodenectomy: A randomized controlled trial. Clinical Nutrition, 2019, 38, 174-181.	5.0	61
54	Antitumor activity of panâ€“HER inhibitors in HER2â€“positive gastric cancer. Cancer Science, 2018, 109, 1166-1176.	3.9	29

#	ARTICLE	IF	CITATIONS
55	A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study). <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 387-392.	2.3	10
56	PS02.222: CLINICAL CHARACTERISTICS AND MANAGEMENT OF GASTRIC TUBE CANCER AFTER ESOPHAGECTOMY. <i>Ecological Management and Restoration</i> , 2018, 31, 185-185.	0.4	0
57	The epithelial-to-mesenchymal transition induced by tumor-associated macrophages confers chemoresistance in peritoneally disseminated pancreatic cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 307.	8.6	75
58	Integrated fluorescent cytology with nano-biologics in peritoneally disseminated gastric cancer. <i>Cancer Science</i> , 2018, 109, 3263-3271.	3.9	11
59	Clinical characteristics and management of gastric tube cancer after esophagectomy. <i>Esophagus</i> , 2018, 15, 180-189.	1.9	16
60	HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 1919-1929.	3.3	52
61	Cancer-Associated Fibroblasts Affect Intratumoral CD8+ and FoxP3+ T Cells Via IL6 in the Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2018, 24, 4820-4833.	7.0	225
62	あーçš'ã^†é†žã«ãšãã,æ-°ã-ã,ã°,é-€ãĈ»ã^ŕãº . <i>Okayama Igakkai Zasshi</i> , 2018, 130, 73-78.	0.0	0
63	Therapeutic Cellâ€Cycleâ€Decoy Efficacy of a Telomeraseâ€Dependent Adenovirus in an Orthotopic Model of Chemotherapyâ€Resistant Human Stomach Carcinomatosis Peritonitis Visualized With Fucci Imaging. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 3635-3642.	2.6	6
64	Eradication of melanoma <i>in vitro</i> and <i>in vivo</i> via targeting with a Killer-Red-containing telomerase-dependent adenovirus. <i>Cell Cycle</i> , 2017, 16, 1502-1508.	2.6	9
65	GFP labeling kinetics of triple-negative human breast cancer by a killer-reporter adenovirus in 3D Gelfoam® histoculture. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2017, 53, 479-482.	1.5	3
66	High-metastatic triple-negative breast-cancer variants selected <i>in vivo</i> become chemoresistant <i>in vitro</i> . <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2017, 53, 285-287.	1.5	3
67	Radiographic sarcopenia predicts postoperative infectious complications in patients undergoing pancreaticoduodenectomy. <i>BMC Surgery</i> , 2017, 17, 64.	1.3	46
68	Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system. <i>Scientific Reports</i> , 2017, 7, 14177.	3.3	23
69	A novel intestinal rotation method for digestive reconstruction after combined pancreaticoduodenectomy and extended right hemicolectomy: A case report and surgical technique. <i>International Journal of Surgery Case Reports</i> , 2017, 39, 51-55.	0.6	0
70	Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction. <i>Cancer Science</i> , 2017, 108, 1870-1880.	3.9	12
71	Comparison of <i>in vitro</i> invasiveness of high- and low-metastatic triple-negative human breast cancer visualized by color-coded imaging. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2017, 53, 96-98.	1.5	3
72	Cell-cycle-dependent drug-resistant quiescent cancer cells induce tumor angiogenesis after chemotherapy as visualized by real-time Fucci imaging. <i>Cell Cycle</i> , 2017, 16, 406-414.	2.6	29

#	ARTICLE	IF	CITATIONS
73	Enhanced Metastatic Recurrence Via Lymphatic Trafficking of a High-Metastatic Variant of Human Triple-Negative Breast Cancer After Surgical Resection in Orthotopic Nude Mouse Models. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 559-569.	2.6	4
74	Impact of Autophagy in Oncolytic Adenoviral Therapy for Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1479.	4.1	41
75	Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers. <i>Oncotarget</i> , 2017, 8, 26122-26128.	1.8	19
76	Iron depletion is a novel therapeutic strategy to target cancer stem cells. <i>Oncotarget</i> , 2017, 8, 98405-98416.	1.8	36
77	Comparison of Tumor Recurrence After Resection of Highly- and Poorly-Metastatic Triple-negative Breast Cancer in Orthotopic Nude-Mouse Models. <i>Anticancer Research</i> , 2017, 37, 57-60.	1.1	4
78	Thoracoscopic esophagectomy was effective in a case of lower esophageal stenosis due to recurrence of achalasia after myotomy 40 years previously. <i>Okayama Igakkai Zasshi</i> , 2017, 129, 41-44.	0.0	0
79	Eradication of osteosarcoma by fluorescence-guided surgery with tumor labeling by a killer-reporter adenovirus. <i>Journal of Orthopaedic Research</i> , 2016, 34, 836-844.	2.3	18
80	Tumor-specific delivery of biologics by a novel T-cell line HOZOT. <i>Scientific Reports</i> , 2016, 6, 38060.	3.3	10
81	Iron depletion-induced downregulation of N-cadherin expression inhibits invasive malignant phenotypes in human esophageal cancer. <i>International Journal of Oncology</i> , 2016, 49, 1351-1359.	3.3	15
82	p53 Replacement Therapy for Cancer. <i>Recent Results in Cancer Research</i> , 2016, 209, 1-15.	1.8	12
83	Iron depletion enhances the effect of sorafenib in hepatocarcinoma. <i>Cancer Biology and Therapy</i> , 2016, 17, 648-656.	3.4	21
84	Tumor-specific cell-cycle decoy by <i>Salmonella typhimurium</i> A1-R combined with tumor-selective cell-cycle trap by methioninase overcome tumor intrinsic chemoresistance as visualized by FUCCI imaging. <i>Cell Cycle</i> , 2016, 15, 1715-1723.	2.6	55
85	Ablation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas. <i>Scientific Reports</i> , 2016, 6, 28953.	3.3	34
86	Efficient detection of human circulating tumor cells without significant production of false-positive cells by a novel conditionally replicating adenovirus. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16001.	4.1	22
87	Targeted Photodynamic Virotherapy Armed with a Genetically Encoded Photosensitizer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 199-208.	4.1	17
88	Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor ⁺ Positive, HER2-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 95-100.e1.	2.4	9
89	Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 402-411.	4.1	23
90	Anti ⁺ high mobility group box 1 monoclonal antibody improves ischemia/reperfusion injury and mode of liver regeneration after partial hepatectomy. <i>American Journal of Surgery</i> , 2016, 211, 179-188.	1.8	13

#	ARTICLE	IF	CITATIONS
91	Improved Resection and Outcome of Colon-Cancer Liver Metastasis with Fluorescence-Guided Surgery Using In Situ GFP Labeling with a Telomerase-Dependent Adenovirus in an Orthotopic Mouse Model. PLoS ONE, 2016, 11, e0148760.	2.5	35
92	Efficacy of a Cell-Cycle Decoying Killer Adenovirus on 3-D Gelfoam®-Histoculture and Tumor-Sphere Models of Chemo-Resistant Stomach Carcinomatosis Visualized by FUCCI Imaging. PLoS ONE, 2016, 11, e0162991.	2.5	3
93	Fluorescence-guided surgery of a highly-metastatic variant of human triple-negative breast cancer targeted with a cancer-specific GFP adenovirus prevents recurrence. Oncotarget, 2016, 7, 75635-75647.	1.8	16
94	Tumor-targeting adenovirus OBP-401 inhibits primary and metastatic tumor growth of triple-negative breast cancer in orthotopic nude-mouse models. Oncotarget, 2016, 7, 85273-85282.	1.8	7
95	Adenoviral targeting of malignant melanoma for fluorescence-guided surgery prevents recurrence in orthotopic nude-mouse models. Oncotarget, 2016, 7, 18558-18572.	1.8	9
96	In Vivo Selection of Intermediately- and Highly- Malignant Variants of Triple-negative Breast Cancer in Orthotopic Nude Mouse Models. Anticancer Research, 2016, 36, 6273-6278.	1.1	11
97	In Vivo Isolation of a Highly-aggressive Variant of Triple-negative Human Breast Cancer MDA-MB-231 Using Serial Orthotopic Transplantation. Anticancer Research, 2016, 36, 3817-20.	1.1	7
98	Surgical Outcome of Patients Undergoing Pancreaticoduodenectomy: Analysis of a 17â€­Year Experience at a Single Center. Acta Medica Okayama, 2016, 70, 197-203.	0.2	7
99	Precise navigation surgery of tumours in the lung in mouse models enabled by in situ fluorescence labelling with a killer-reporter adenovirus. BMJ Open Respiratory Research, 2015, 2, e000096.	3.0	29
100	Operative technique of antethoracic esophageal reconstruction with pedicled jejunal flap. Esophagus, 2015, 12, 57-64.	1.9	2
101	Viral transduction of the HER2-extracellular domain expands trastuzumab-based photoimmunotherapy for HER2-negative breast cancer cells. Breast Cancer Research and Treatment, 2015, 149, 597-605.	2.5	24
102	Biological Ablation of Sentinel Lymph Node Metastasis in Submucosally Invaded Early Gastrointestinal Cancer. Molecular Therapy, 2015, 23, 501-509.	8.2	9
103	Cell-cycle fate-monitoring distinguishes individual chemosensitive and chemoresistant cancer cells in drug-treated heterogeneous populations demonstrated by real-time FUCCI imaging. Cell Cycle, 2015, 14, 621-629.	2.6	23
104	Prone-position thoracoscopic resection of posterior mediastinal lymph node metastasis from rectal cancer. World Journal of Surgical Oncology, 2015, 13, 45.	1.9	4
105	The rare BRAF VK600-601E mutation as a possible indicator of poor prognosis in rectal carcinoma â€­ a report of a case. BMC Medical Genetics, 2015, 16, 1.	2.1	24
106	Cancer cells mimic <i>in vivo</i> spatial-temporal cell-cycle phase distribution and chemosensitivity in 3-dimensional Gelfoam® histoculture but not 2-dimensional culture as visualized with real-time FUCCI imaging. Cell Cycle, 2015, 14, 808-819.	2.6	33
107	Heterogeneous cell-cycle behavior in response to UVB irradiation by a population of single cancer cells visualized by time-lapse FUCCI imaging. Cell Cycle, 2015, 14, 1932-1937.	2.6	6
108	Experimental Curative Fluorescence-guided Surgery of Highly Invasive Glioblastoma Multiforme Selectively Labeled With a Killer-reporter Adenovirus. Molecular Therapy, 2015, 23, 1182-1188.	8.2	37

#	ARTICLE	IF	CITATIONS
109	Fluorescence virus-guided capturing system of human colorectal circulating tumour cells for non-invasive companion diagnostics. <i>Gut</i> , 2015, 64, 627-635.	12.1	27
110	Targeting tumors with a killer-reporter adenovirus for curative fluorescence-guided surgery of soft-tissue sarcoma. <i>Oncotarget</i> , 2015, 6, 13133-13148.	1.8	45
111	Tumor-targeting <i>Salmonella typhimurium</i> A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy. <i>Cell Cycle</i> , 2014, 13, 3958-3963.	2.6	96
112	Spatial-temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsiveness. <i>Cell Cycle</i> , 2014, 13, 2110-2119.	2.6	69
113	Selectively Replicating Oncolytic Adenoviruses Combined with Chemotherapy, Radiotherapy, or Molecular Targeted Therapy for Treatment of Human Cancers. , 2014, , 171-183.		5
114	Invading cancer cells are predominantly in G ₀ /G ₁ resulting in chemoresistance demonstrated by real-time FUCCI imaging. <i>Cell Cycle</i> , 2014, 13, 953-960.	2.6	67
115	Establishment of a Non-Invasive Semi-Quantitative Bioluminescent Imaging Method for Monitoring of an Orthotopic Esophageal Cancer Mouse Model. <i>PLoS ONE</i> , 2014, 9, e114562.	2.5	15
116	Selective methioninase-induced trap of cancer cells in S/G2 phase visualized by FUCCI imaging confers chemosensitivity. <i>Oncotarget</i> , 2014, 5, 8729-8736.	1.8	85
117	Molecular diagnosis and therapy for occult peritoneal metastasis in gastric cancer patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 17796-17803.	3.3	28
118	Assistant-based standardization of prone position thoracoscopic esophagectomy. <i>Acta Medica Okayama</i> , 2014, 68, 111-7.	0.2	5
119	Dynamic color-coded fluorescence imaging of the cell-cycle phase, mitosis, and apoptosis demonstrates how caffeine modulates cisplatin efficacy. <i>Journal of Cellular Biochemistry</i> , 2013, 114, 2454-2460.	2.6	21
120	Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 639-652.	4.2	37
121	Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 937-943.	2.3	9
122	A novel synergistic effect of iron depletion on antiangiogenic cancer therapy. <i>International Journal of Cancer</i> , 2013, 132, 2705-2713.	5.1	27
123	Advances in adenovirus-mediated p53 cancer gene therapy. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1569-1583.	3.1	50
124	Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice. <i>International Journal of Cancer</i> , 2013, 132, 1451-1462.	5.1	21
125	Dual Programmed Cell Death Pathways Induced by p53 Transactivation Overcome Resistance to Oncolytic Adenovirus in Human Osteosarcoma Cells. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 314-325.	4.1	54
126	A Genetically Engineered Oncolytic Adenovirus Decoys and Lethally Traps Quiescent Cancer Stem-like Cells in S/G2/M Phases. <i>Clinical Cancer Research</i> , 2013, 19, 6495-6505.	7.0	70

#	ARTICLE	IF	CITATIONS
127	Telomelysin shows potent antitumor activity through apoptotic and non-apoptotic cell death in soft tissue sarcoma cells. <i>Cancer Science</i> , 2013, 104, 1178-1188.	3.9	5
128	Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines. <i>Oncology Reports</i> , 2013, 30, 2659-2664.	2.6	9
129	Oncolytic adenovirus-induced autophagy: tumor-suppressive effect and molecular basis. <i>Acta Medica Okayama</i> , 2013, 67, 333-42.	0.2	20
130	Telomerase-specific virotherapy targeting lymph node micrometastasis of human cancer. <i>Okayama Igakkai Zasshi</i> , 2013, 125, 9-12.	0.0	0
131	Synergistic Interaction of Telomerase-Specific Oncolytic Virotherapy and Chemotherapeutic Agents for Human Cancer. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 1809-1816.	1.6	10
132	In Vivo Imaging of Human Cancer with Telomerase-Specific Replication-Selective Adenovirus. <i>Methods in Molecular Biology</i> , 2012, 872, 129-139.	0.9	0
133	Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1905-1916.	4.2	22
134	A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression. <i>European Journal of Cancer</i> , 2012, 48, 2282-2291.	2.8	44
135	The hTERT Promoter Enhances the Antitumor Activity of an Oncolytic Adenovirus under a Hypoxic Microenvironment. <i>PLoS ONE</i> , 2012, 7, e39292.	2.5	16
136	Genetically engineered oncolytic adenovirus induces autophagic cell death through an E2F1-microRNA-7-epidermal growth factor receptor axis. <i>International Journal of Cancer</i> , 2012, 131, 2939-2950.	5.1	49
137	Preventive Effect of Omental Flap in Pancreaticoduodenectomy against Postoperative Pseudoaneurysm Formation. <i>Hepato-Gastroenterology</i> , 2012, 59, 578-83.	0.5	15
138	MicroRNAs as potential target gene in cancer gene therapy of gastrointestinal tumors. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 145-155.	3.1	32
139	Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small cell lung cancer cells. <i>Cancer Science</i> , 2011, 102, 1344-1349.	3.9	32
140	Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1037-1051.	2.5	28
141	Preclinical Evaluation of Telomerase-Specific Oncolytic Virotherapy for Human Bone and Soft Tissue Sarcomas. <i>Clinical Cancer Research</i> , 2011, 17, 1828-1838.	7.0	46
142	Enhanced Safety Profiles of the Telomerase-Specific Replication-Competent Adenovirus by Incorporation of Normal Cell-Specific microRNA-Targeted Sequences. <i>Clinical Cancer Research</i> , 2011, 17, 2807-2818.	7.0	37
143	Tumor-selective, adenoviral-mediated GFP genetic labeling of human cancer in the live mouse reports future recurrence after resection. <i>Cell Cycle</i> , 2011, 10, 2737-2741.	2.6	73
144	Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 525-532.	2.4	14

#	ARTICLE	IF	CITATIONS
145	A novel molecular therapy using bioengineered adenovirus for human gastrointestinal cancer. <i>Acta Medica Okayama</i> , 2011, 65, 151-62.	0.2	10
146	Radiosensitization by telomerase-dependent oncolytic adenovirus. <i>Okayama Igakkai Zasshi</i> , 2011, 123, 103-109.	0.0	0
147	In Vivo Biological Purging for Lymph Node Metastasis of Human Colorectal Cancer by Telomerase-Specific Oncolytic Virotherapy. <i>Annals of Surgery</i> , 2010, 251, 1079-1086.	4.2	25
148	Preclinical Evaluation of Differentially Targeting Dual Virotherapy for Human Solid Cancer. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1884-1893.	4.1	22
149	Telomerase-Dependent Oncolytic Adenovirus Sensitizes Human Cancer Cells to Ionizing Radiation via Inhibition of DNA Repair Machinery. <i>Cancer Research</i> , 2010, 70, 9339-9348.	0.9	70
150	A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors. <i>Molecular Therapy</i> , 2010, 18, 429-434.	8.2	223
151	Targeted Oncolytic Adenovirus for Human Cancer Therapy: Gene-Based Therapies for Cancer. , 2010, , 79-93.		1
152	Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 980-987.	4.1	49
153	Telomerase-specific virotherapy for human squamous cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 321-329.	3.1	11
154	Telomerase-Specific Virotheranostics for Human Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 2335-2343.	7.0	28
155	Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 3001-3008.	4.1	60
156	Telomerase-specific virotherapy in an animal model of human head and neck cancer. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 171-177.	4.1	10
157	Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin). <i>Investigational New Drugs</i> , 2009, 27, 241-245.	2.6	6
158	In vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 14514-14517.	7.1	134
159	Therapeutic Targets and Drugs IV: Telomerase-Specific Gene and Vector-Based Therapies for Human Cancer. , 2009, , 293-312.		2
160	A simple biological imaging system for detecting viable human circulating tumor cells. <i>Journal of Clinical Investigation</i> , 2009, 119, 3172-3181.	8.2	94
161	Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. <i>Cancer Science</i> , 2008, 99, 385-390.	3.9	59
162	Understanding and exploiting <i>hTERT</i> promoter regulation for diagnosis and treatment of human cancers. <i>Cancer Science</i> , 2008, 99, 1528-1538.	3.9	311

#	ARTICLE	IF	CITATIONS
163	Telomerase-Specific Oncolytic Virotherapy for Human Cancer with the hTERT Promoter. <i>Uirusu</i> , 2008, 58, 11-18.	0.1	7
164	Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents. <i>Frontiers in Bioscience - Landmark</i> , 2008, 13, 1881.	3.0	9
165	Adenoviral p53 Gene Therapy for Lung Cancer. <i>Okayama Igakkai Zasshi</i> , 2008, 119, 229-234.	0.0	0
166	XVI ã€Ā, “ã€Ā3/4ã€Ā™ã€Ā,ã€Ā1/4ã€Ā2»ç™,ã€Āç3/4ã€Ā3ã€Ā±ã€Āœ. <i>Okayama Igakkai Zasshi</i> , 2008, 120, 321-327.	0.0	0
167	Telomerase-Specific Oncolytic Virotherapy for Human Cancer with the hTERT Promoter. <i>Current Cancer Drug Targets</i> , 2007, 7, 191-201.	1.6	57
168	In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. <i>Nature Medicine</i> , 2006, 12, 1213-1219.	30.7	161
169	Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: Preclinical evaluation of chemovirotherapy. <i>International Journal of Cancer</i> , 2006, 119, 432-440.	5.1	75
170	Multicenter Phase I Study of Repeated Intratumoral Delivery of Adenoviral p53 in Patients With Advanced Nonã€Ā“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 1689-1699.	1.6	78
171	Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 (ã€ĀTelomelysin-RGDã€Ā™). <i>Oncogene</i> , 2005, 24, 3130-3140.	5.9	78
172	Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. <i>Experimental Cell Research</i> , 2005, 312, 256-65.	2.6	75
173	ZD1839 (Gefitinib, ã€ĀIressã€Ā™), an epidermal growth factor receptorã€Ātyrosine kinase inhibitor, enhances the antiã€Ācancer effects of TRAIL in human esophageal squamous cell carcinoma. <i>FEBS Letters</i> , 2005, 579, 4069-4075.	2.8	59
174	Telomerase-Specific Replication-Selective Virotherapy for Human Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 285-292.	7.0	230
175	Visualization of Intrathoracically Disseminated Solid Tumors in Mice with Optical Imaging by Telomerase-Specific Amplification of a Transferred Green Fluorescent Protein Gene. <i>Cancer Research</i> , 2004, 64, 6259-6265.	0.9	69
176	Antitumor Effect of Intratumoral Administration of Bone Marrow-Derived Dendritic Cells Transduced with Wild-Type p53 Gene. <i>Clinical Cancer Research</i> , 2004, 10, 3871-3880.	7.0	24
177	Late resistance to adenoviral p53-mediated apoptosis caused by decreased expression of Coxsackie-adenovirus receptors in human lung cancer cells. <i>Cancer Science</i> , 2004, 95, 459-463.	3.9	19
178	Ectopic p21sdi1 gene transfer induces retinoic acid receptor ? expression and sensitizes human cancer cells to retinoid treatment. <i>International Journal of Cancer</i> , 2003, 103, 833-839.	5.1	25
179	Adenovirus-Mediated p14ARFGene Transfer Cooperates with Ad5CMV-p53 to Induce Apoptosis in Human Cancer Cells. <i>Human Gene Therapy</i> , 2002, 13, 1373-1382.	2.7	21
180	The Mechanism of Actinomycin Dã€ĀMediated Increase of Borna Disease Virus (BDV) RNA in Cells Persistently Infected by BDV. <i>Microbiology and Immunology</i> , 2000, 44, 597-603.	1.4	6

#	ARTICLE	IF	CITATIONS
181	Overexpression of the wild-type p53 gene inhibits NF- κ B activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. <i>Oncogene</i> , 2000, 19, 726-736.	5.9	134
182	Contribution of CD95 Ligand-Induced Neutrophil Infiltration to the Bystander Effect in p53 Gene Therapy for Human Cancer. <i>Journal of Immunology</i> , 2000, 165, 5884-5890.	0.8	46
183	Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells. <i>Oncogene</i> , 1999, 18, 2189-2199.	5.9	72
184	p53 expression overcomes p21WAF1/CIP1-mediated G1 arrest and induces apoptosis in human cancer cells. <i>Oncogene</i> , 1997, 15, 1903-1909.	5.9	84
185	Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. , 1997, 73, 367-370.		50